Lacticaseibacillus rhamnosus TOM 22.8 (DSM 33500) is an effective strategy for managing vaginal dysbiosis, rising the lactobacilli population
Journal of Applied Microbiology · 01.05.2024 · 135 (5)
DOI: 10.1093/jambio/lxae110 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Applied Microbiology, online erschienen am 16.05.2024. Verfasst von Amanda Vaccalluzzo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Agriculture, Food and Environment, University of Catania, Santa Sofia Street, 100, 95123 Catania, Italy. Hauptthemen laut MEDLINE: Probiotics, Lacticaseibacillus rhamnosus, Dysbiosis, Vagina. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uriach.
Abstract (Originalsprache)
Aim
The present study is a single-centre, randomized, controlled clinical trial aimed to evaluate the effectiveness of the probiotic Lacticaseibacillus rhamnosus TOM 22.8 (DSM 33500) strain, orally administrated, to treat vaginal dysbiosis. Methods and Results Overall, 80 women, with signs and symptoms of vaginal dysbiosis, were enrolled and allocated to the treatment group (A, n=60), who took 1 capsule of the probiotic strain for 10 consecutive days, or the non-treatment group (B, n=20), who did not receive any treatment. Clinical (vaginal signs and symptoms; pH of the vaginal fluid; Amsel criteria; Nugent score; Lactobacillary grade) and microbiological examinations were performed at baseline (T0), 10 days (T1), and 30 (T2) days after the oral administration of the probiotic TOM 22.8 strain. The latter resulted in a restoration of the physiological pH, accompanied by remission or attenuation of clinical signs and symptoms as well as the improvement of the quality of life (QoL). Microbiological data revealed a significant reduction of potentially pathogenic bacteria.
Conclusion
The administration of the L. rhamnosus TOM 22.8 probiotic strain could be proposed as an effective strategy for the treatment of vaginal dysbiosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Agriculture, Food and Environment, University of Catania, Santa Sofia Street, 100, 95123 Catania, Italy.
- ProBioEtna SRL, Spin off of the University of Catania, Santa Sofia Street, 100, 95123 Catania, Italy.
- Department of General Surgery and Medical Surgical Specialties, University of Catania, Santa Sofia Street, 78, 95123 Catania, Italy.
- Unit of Gynecology and Obstetrics, Department of Human Pathology of Adult and Childhood "G. Barresi", University of Messina, 98122 Messina, Italy.
ORCID-Profile: Alessandra Pino
Förderung
- Uriach
Zitieren
APA
Vaccalluzzo, A., Pino, A., Grimaldi, R. L., Caggia, C., Cianci, S., & Randazzo, C. L. (2024). Lacticaseibacillus rhamnosus TOM 22.8 (DSM 33500) is an effective strategy for managing vaginal dysbiosis, rising the lactobacilli population. Journal of Applied Microbiology, 135(5). https://doi.org/10.1093/jambio/lxae110
Vancouver
Vaccalluzzo A, Pino A, Grimaldi RL, Caggia C, Cianci S, Randazzo CL. Lacticaseibacillus rhamnosus TOM 22.8 (DSM 33500) is an effective strategy for managing vaginal dysbiosis, rising the lactobacilli population. Journal of Applied Microbiology. 2024;135(5). doi:10.1093/jambio/lxae110
BibTeX
@article{Vaccalluzzo2024,
author = {Vaccalluzzo, Amanda and Pino, Alessandra and Grimaldi, Raffaela Luisa and Caggia, Cinzia and Cianci, Stefano and Randazzo, Cinzia Lucia},
title = {Lacticaseibacillus rhamnosus TOM 22.8 (DSM 33500) is an effective strategy for managing vaginal dysbiosis, rising the lactobacilli population},
journal = {Journal of Applied Microbiology},
year = {2024},
volume = {135},
number = {5},
doi = {10.1093/jambio/lxae110}
}
EUVIMED